Drug intelligence / Profile preview

HCP1902

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules

Overview

HCP1902 is a small molecule drug developed by Hanmi Pharmaceutical. It has been evaluated in at least one completed Phase 1 clinical trial to assess its pharmacokinetic characteristics and safety compared to the co-administration of RLD2007 and RLD2008 in healthy volunteers. The specific mechanism of action, therapeutic area, and active indication for HCP1902 have not been disclosed in publicly available sources as of June 2025[1][2][5].

Beyond the preview

Go deeper on HCP1902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCP1902.

Explore the full profile